Since 1991, hydroxychloroquine (HCQ) has been a staple for the treatment of patients with systemic lupus erythematosus; it has been shown to improve survival, reduce cardiovascular risk, thrombosis and renal damage, delay or prevent lupus cerebritis and more. However, HCQ can potentially bind in the retinal pigment epithelium and cause degeneration of photoreceptors, leading to…
Patients with conditions that don’t resolve with topical steroids are signal for referral
Recommendations on diagnosing, treating health conditions that cross over both specialties
Reactive arthritis has proved to be a diagnostic & therapeutic challenge due to its diverse presentations.
Rheumatologists must do some detective work into a patient’s signs and symptoms when considering a psoriatic arthritis diagnosis, according to Philip J. Mease, MD, MACR
Jun Kang, MD, addressed the intersection of dermatology and rheumatology, describing the nuance necessary to accurately evaluate skin manifestations and differentiate multiple conditions.
SAN DIEGO—Differences between psoriatic arthritis and rheumatoid arthritis highlight the need for the development of imaging modalities, laboratory tests and other biomarkers that are explored and validated specifically for PsA to advance the goal of personalized or precision medicine. In this article, expert David S. Pisetsky, MD, PhD, explores the top research in psoriatic arthritis presented at ACR Convergence 2023.
Misinformation, fear and not having a trusted partner in the medical sector are just a few of the barriers that prevent patients of color from being adequately represented in research and clinical trials for lupus. Experts and patient advocates addressed how to remove these barriers and more during the 2023 ACR Diversification of Clinical Trials Summit.
ORLANDO, FLORIDA — Given the intersection between rheumatology and dermatology for many patients with autoimmune diseases, it’s helpful to hear from specialists in both fields regarding disease management strategies.
Now in the second year of his 2021–2023 term as the Rheumatology Research Foundation president, V. Michael Holers, MD, a professor of medicine and immunology and the Smyth Professor of Rheumatology at the University of Colorado, Denver, is looking forward to fortifying and expanding the Foundation’s missions in the framework of its new strategic plan.